William Blair Investment Management LLC Reduces Position in Insmed, Inc. $INSM

William Blair Investment Management LLC cut its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 21.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,221,096 shares of the biopharmaceutical company’s stock after selling 333,961 shares during the quarter. William Blair Investment Management LLC’s holdings in Insmed were worth $212,520,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in INSM. Artisan Partners Limited Partnership boosted its holdings in Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after purchasing an additional 1,623,342 shares during the last quarter. Atika Capital Management LLC purchased a new stake in Insmed in the third quarter valued at $13,681,000. iA Global Asset Management Inc. boosted its holdings in Insmed by 15,973.5% in the fourth quarter. iA Global Asset Management Inc. now owns 26,682 shares of the biopharmaceutical company’s stock valued at $4,644,000 after purchasing an additional 26,516 shares during the last quarter. Nordea Investment Management AB purchased a new stake in Insmed in the fourth quarter valued at $3,492,000. Finally, Keybank National Association OH boosted its holdings in Insmed by 76.7% in the third quarter. Keybank National Association OH now owns 16,716 shares of the biopharmaceutical company’s stock valued at $2,407,000 after purchasing an additional 7,257 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts have commented on INSM shares. Mizuho upped their price target on shares of Insmed from $204.00 to $206.00 and gave the company an “outperform” rating in a report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a report on Tuesday, April 21st. Royal Bank Of Canada lowered their price target on shares of Insmed from $220.00 to $205.00 and set an “outperform” rating on the stock in a report on Friday, May 8th. Leerink Partners upped their price target on shares of Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a report on Tuesday, March 24th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $210.95.

Insiders Place Their Bets

In other Insmed news, COO Roger Adsett sold 88,060 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total value of $14,497,317.80. Following the completion of the transaction, the chief operating officer owned 106,810 shares in the company, valued at approximately $17,584,130.30. This represents a 45.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO William Lewis sold 10,699 shares of the company’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $143.52, for a total transaction of $1,535,520.48. Following the completion of the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at approximately $43,226,071.20. This trade represents a 3.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 156,643 shares of company stock worth $24,513,766. Company insiders own 2.10% of the company’s stock.

Insmed Trading Down 3.0%

Shares of Insmed stock opened at $106.24 on Friday. The firm has a 50-day simple moving average of $137.89 and a two-hundred day simple moving average of $160.87. The company has a market cap of $23.03 billion, a P/E ratio of -18.48 and a beta of 0.89. Insmed, Inc. has a fifty-two week low of $65.56 and a fifty-two week high of $212.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. The business had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company’s revenue was up 229.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.42) earnings per share. As a group, equities analysts predict that Insmed, Inc. will post -2.52 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.